
No image published for this recall
Cardiosave system - hybrid & rescue intra-aortic balloon pump
Official notice
14 Aug 2023
Last checked
14 Aug 2023
An official Health Canada notice concerns Cardiosave system - hybrid & rescue intra-aortic balloon pump. Manufacturer notifying its customers regarding the following four identified system conditions: Issue 1 - autofill alarms: manufacturer received multiple complaints where Cardiosave IABP users were identifying autofill failure conditions on the devices. For those autofill failures that result from an equipment failure that the user cannot address directly, a prolonged interruption may be experienced until an alternative console can be identified. Further, if one is not available, or the patient is in transport, therapy cannot be continued. If alternative supportive measures are unavailable or ineffective until therapy can be resumed, therapy interruption can lead to death. Issue 2 - gas loss & gas gain alarms: manufacturer received multiple complaints where Cardiosave IABP users were reporting instances of "gas loss in IAB circuit" and "gas gain in IAB circuit" alarms while providing therapy. A delay in therapy or an interruption in therapy may be experienced while troubleshooting the patient alarm. Should the gas loss/gas gain failure result in prolonged interruption to therapy due to the inability to successfully troubleshoot the alarm (e.g., a component failure), the hospital will need to obtain a different console. If another IABP console is not available for use, alternative means of providing hemodynamic support (vasopressors, inotropes or alternate therapies) may be initiated by a healthcare provider as a temporizing measure. If alternative supportive measures are unavailable or ineffective until therapy can be resumed, therapy interruption can lead to death. Issue 3 - system over-temperature: manufacturer received multiple complaints wherein users reported "system over temperature" alarms associated with a loss of pumping and/or the Cardiosave system entering standby mode. Should the IABP internal temperature exceed a threshold of 80° c, the Cardiosave interrupts therapy by placing the pump in standby and notifies the user of the event. Although the user is notified of the event by both audible and visual notification, the resulting standby mode is sudden and requires immediate user intervention to either provide alternative or supportive therapy to the patient. If alternative supportive measures are unavailable or ineffective until therapy can be resumed, therapy interruption can lead to death. Issue 4 - fiber optic damage: manufacturer received multiple complaints where Cardiosave IABP users were experiencing a failure in the IAB fiber optic sensor input on the IABP when inserting the intra-aortic balloon fiber optic connector. Should the event occur where fiber optic signal is not available and there is no ECG signal available, therapy may be interrupted. If alternative supportive measures are unavailable or ineffective until therapy can be resumed, therapy interruption can lead to death. This urgent medical device notification is being issued by the manufacturer to inform users of the issues observed and actions to be taken should users experience these issues. Recall start date: August 4, 2023 Published 2023-08-14.
What to do now
Contact the manufacturer if you require additional information.
Recall number
74110
Official notice
2023-08-14
The hazard
The hazard
Manufacturer notifying its customers regarding the following four identified system conditions: Issue 1 - autofill alarms: manufacturer received multiple complaints where Cardiosave IABP users were identifying autofill failure conditions on the devices. For those autofill failures that result from an equipment failure that the user cannot address directly, a prolonged interruption may be experienced until an alternative console can be identified. Further, if one is not available, or the patient is in transport, therapy cannot be continued. If alternative supportive measures are unavailable or ineffective until therapy can be resumed, therapy interruption can lead to death. Issue 2 - gas loss & gas gain alarms: manufacturer received multiple complaints where Cardiosave IABP users were reporting instances of "gas loss in IAB circuit" and "gas gain in IAB circuit" alarms while providing therapy. A delay in therapy or an interruption in therapy may be experienced while troubleshooting the patient alarm. Should the gas loss/gas gain failure result in prolonged interruption to therapy due to the inability to successfully troubleshoot the alarm (e.g., a component failure), the hospital will need to obtain a different console. If another IABP console is not available for use, alternative means of providing hemodynamic support (vasopressors, inotropes or alternate therapies) may be initiated by a healthcare provider as a temporizing measure. If alternative supportive measures are unavailable or ineffective until therapy can be resumed, therapy interruption can lead to death. Issue 3 - system over-temperature: manufacturer received multiple complaints wherein users reported "system over temperature" alarms associated with a loss of pumping and/or the Cardiosave system entering standby mode. Should the IABP internal temperature exceed a threshold of 80° c, the Cardiosave interrupts therapy by placing the pump in standby and notifies the user of the event. Although the user is notified of the event by both audible and visual notification, the resulting standby mode is sudden and requires immediate user intervention to either provide alternative or supportive therapy to the patient. If alternative supportive measures are unavailable or ineffective until therapy can be resumed, therapy interruption can lead to death. Issue 4 - fiber optic damage: manufacturer received multiple complaints where Cardiosave IABP users were experiencing a failure in the IAB fiber optic sensor input on the IABP when inserting the intra-aortic balloon fiber optic connector. Should the event occur where fiber optic signal is not available and there is no ECG signal available, therapy may be interrupted. If alternative supportive measures are unavailable or ineffective until therapy can be resumed, therapy interruption can lead to death. This urgent medical device notification is being issued by the manufacturer to inform users of the issues observed and actions to be taken should users experience these issues. Recall start date: August 4, 2023
How to check if you're affected
How to check if you're affected
Compare the product name and identifiers below with the item you own. Follow the official notice if they match.
Recall Numbers
Checked manually this time?
The app alerts you when a new official recall is published — no searching, no checking back.
Turn on recall alertsAffected products
Affected products
Product 1
Risk / hazard
Where it was sold
Where it was sold
The source does not list specific retailers. See the official notice for where affected products were sold.
Location 1
Affected area 1
Company & contacts
Company & contacts
Manufacturer
Phone
Brand: Datascope, Cardiosave System - Hybrid Rescue Intra-aortic Balloon Pump.
Source & status
Source & status
Source
Tier
Category
Classification
App estimate
Recall details
Recall details
Recall number
Classification
Source tier
Documents, notices & source
See the official notice and source documents for full details.
View full official noticeWeekly recall digest
Get next week's recalls before you need them.
One email every Monday — official-source recalls for your country, and nothing else. Unsubscribe from any email.
The digest is the slow lane — one email a week. For instant, severity-gated alerts the moment a notice is published, get the app.
This recall was published 14 Aug 2023. The next one won't wait for you to search.
RecallScope watches official sources for the brands and VINs you follow, and alerts you the moment a new notice is published.